Product Description
ELE-101, also known as ELE-Psilo, is an IV infusion for adults with treatment resistant depression. (Sourced from: https://assets.ctfassets.net/k3ab1qydxt75/lHH6ba1QeONN47A0R2cEt/461b4cf7bf5cd6c641f5c6c74358ac26/Eleusis_Investor_Deck_-_Final_2022.02.08.pdf)
Mechanisms of Action: 5-HT2A Agonist
Novel Mechanism: No
Modality: Unknown
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eleusis Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Depressive Disorder, Major
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05434156 |
ET1001-ELE-101 | P2 |
Active, not recruiting |
Depressive Disorder, Major |
2025-12-01 |
2% |
2025-02-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |